Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Zydus Lifesciences buyback alert! Last date to buy shares to participate in Rs 1,100 crore buyback at 7% premium
Investors must purchase Zydus Lifesciences shares by Wednesday, May 27, to be eligible for the Rs 1,100 crore buyback, as the record date is May 29. The company approved buying back up to 95.65 lakh shares at Rs 1,150 each, a 7% premium. This follows strong Q4 results and a dividend recommendation.
6 pharma stocks that Bernstein sees up to 40% upside potential. Do you own any?
Bernstein initiated coverage on six pharma stocks, expressing a positive outlook on the Indian healthcare sector driven by AI, innovation in niche areas, and a strengthening ecosystem. The brokerage highlighted attractive valuations and easing policy uncertainties, naming Zydus Lifesciences as its top pick with a significant upside potential.
Sakar Healthcare partners with Zydus Lifesciences for GCC Markets
Sakar Healthcare has partnered with Zydus Lifesciences to supply oncology products in GCC countries and other emerging markets. This marks the company's 40th global agreement in the anti-cancer segment. Sakar Healthcare is expanding its international oncology business and strengthening its presence in emerging markets. The company is also progressing with regulatory filings and approvals in highly regulated markets.
Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sector
Bernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future growth for the Indian healthcare sector. Key drivers include AI-led innovation, incremental advancements in niche areas, and improved quality culture. Attractive valuations also support this positive outlook for the industry.
Zydus Lifesciences concludes its investment in Torrent Urja 25
Pursuant to the same, the transaction of subscription of shares of Torrent Urja 25 is consummated on 19 May 2026.
Zydus Lifesciences shares soar 7% to fresh record high after Q4 results. Should you buy, sell or hold?
Zydus Lifesciences shares climbed to a new 52-week high. The company reported a 9% rise in net profit and over 16% revenue growth for the January-March quarter. A Rs 1,100 crore share buyback was announced. Analysts from Nomura, Nuvama, Motilal Oswal, and JM Financial shared their views on the company's performance and future prospects.
Zydus Lifesciences Shares Rally After Q4 Result, Share Buyback Announcement
The sharp rally comes on the back of Zydus Life's Q4FY26 earnings, where the company reported a consolidated net profit of Rs 1,272.5 crore for the March quarter, up 8.7% year-on-year.
Zydus Lifesciences shares gain 7%, hit 52-week high on healthy Q4 show
In the March quarter (Q4FY26), Zydus Lifesciences reported a net profit of ₹1,272.5 crore, as compared to ₹1,170.9 crore a year ago, up 8.7 per cent
Zydus Lifesciences share price jumps over 6% after Q4 results. Should you buy or sell?
Zydus Lifesciences shares rose over 6% after strong Q4FY26 earnings, reporting a 14.6% increase in net profit to ₹1,592.9 crore. Revenue grew to ₹7,587 crore, driven by the consumer wellness segment. The board approved a ₹1,100 crore share buyback and a Re 1 dividend.
Zydus LifeSciences Shares in Focus: Motilal Oswal Maintains Neutral Rating on Limited Upside — Check Revised Target Price
The current valuation provides limited upside and hence, Motilal Oswal has maintained Neutral rating on Zydus Lifesciences.
Zydus Lifesciences to pursue acquisitions in specialty, rare diseases
Zydus Lifesciences is set to acquire US firm Assertio Holdings for $166.40 million. This move aims to build a strong specialty oncology business in the US. The company reported robust financial growth for the fourth quarter of 2025-26. Zydus also announced a share buyback and a dividend. Future growth is expected from its specialty portfolio.
Zydus Lifesciences beats estimates, sees high-teens growth in FY27
For FY26, its revenue from operations stood at ₹27,148.4 crore, up 17% on-year, and adjusted net profit grew 15% to ₹5,456.4 crore.